Novel immuno-polymerase chain reaction assay detects CJC-1295 in equine plasma down to 0.8 pg/mL
Background
CJC-1295 is a 30-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH) designed to stimulate the release of growth hormone from the pituitary gland. Its unique structure includes a reactive maleimidopropionic acid group, which allows it to form a covalent bond with free thiols on plasma proteins like albumin. This conjugation dramatically extends its half-life in the bloodstream compared to non-conjugated peptides, which are rapidly cleared. However, this same mechanism makes it a challenge for anti-doping laboratories. By binding to proteins, CJC-1295 becomes a macromolecule with an undefined molecular weight, rendering it undetectable by standard top-down mass-spectrometry screening protocols.
Study Design
To overcome this detection challenge, researchers developed a novel assay. They raised a pair of monoclonal antibodies specifically against the CJC-1295 peptide. Using these antibodies, they designed an immuno-polymerase chain reaction (I-PCR) assay. This technique combines the specificity of an antibody-based immunoassay with the signal amplification power of polymerase chain reaction. The assay was tested on equine plasma samples to determine its sensitivity and specificity for detecting the CJC-1295-protein conjugate. The method's effectiveness was then confirmed by analyzing blood samples from thoroughbred race horses after they had been administered CJC-1295.
Results
The newly developed I-PCR assay demonstrated remarkable sensitivity for detecting the CJC-1295-protein conjugate. The assay was capable of identifying the substance at concentrations down to 0.8 pg/mL. However, the researchers noted that the assay also detected endogenous equine GHRH. To avoid false positives and reliably distinguish illicit use from natural hormone presence, a screening threshold for CJC-1295 in equine plasma was established. This threshold was set significantly higher than the assay's lower limit of detection to ensure specificity in a real-world anti-doping context. The study confirmed the assay's practical utility in controlling the misuse of CJC-1295.
The screening threshold for CJC-1295 in equine plasma was set at 50 pg/mL to account for cross-reactivity with endogenous GHRH.
Key Findings
- A new immuno-polymerase chain reaction (I-PCR) assay was developed to detect CJC-1295.
- The assay detects the CJC-1295-protein conjugate at concentrations down to 0.8 pg/mL.
- Due to cross-reactivity with endogenous equine GHRH, a screening threshold was set at 50 pg/mL.
- The assay was successfully validated in blood samples from thoroughbred race horses administered CJC-1295.
Why It Matters
This I-PCR assay represents a significant leap forward for anti-doping in equine sports and potentially beyond. Standard mass spectrometry methods are blind to CJC-1295 once it binds to plasma proteins, creating a major loophole for illicit use. This new method closes that gap, making detection of long-acting GHRH analogs feasible and highly sensitive. For regulators and athletes, this means that even microdoses of covalently-bound peptides like CJC-1295 are now detectable for extended periods post-administration. This development could force a re-evaluation of doping strategies, rendering peptides previously thought to be 'invisible' easily identifiable. The principles of this assay could also be adapted to detect other performance-enhancing peptides that use similar protein conjugation technologies to evade detection.
TitrateLab articles covering CJC-1295
Written by TitrateLab, separately from the study summarized above.
cjc-1295
ghrh
growth hormone
anti-doping
lab methodology
assay development
